Tesamorelin Regulatory Status: FDA Approval and Compounding Context
Why tesamorelin's story is different from most peptides Halftime Health discusses.
TL;DR
Tesamorelin is FDA-approved as the brand Egrifta, for one use: reducing excess abdominal fat in adults with HIV and lipodystrophy (in plain English: abnormal fat buildup linked to HIV treatment). Other uses are not approved and not established. A compounded version is not itself FDA-approved.
What tesamorelin FDA approval status means
Tesamorelin holds real FDA approval, but only for a narrow use. The Food and Drug Administration (FDA) approved Egrifta in 2010 to reduce excess abdominal fat in adults with HIV and lipodystrophy. Visceral adipose tissue is fat stored around internal organs, not just under the skin. Other uses are not approved and not established, and compounded tesamorelin is a separate regulatory category entirely.
How the approval-vs-compounding distinction works
Think of a car built at a factory versus one a local mechanic assembles. Egrifta is the factory-built car: FDA reviewed its manufacturing, testing, and trial data. Compounded tesamorelin is the mechanic's car: its own parts and process, and no agency sign-off on the finished product.
Who asks about it
People managing HIV-related fat redistribution ask about tesamorelin most often. Others ask after hearing about its growth hormone-releasing hormone (GHRH) mechanism for general visceral fat, which is an unapproved use that has not been established.
What the research says
Falutz et al., published in the New England Journal of Medicine in 2007, found tesamorelin reduced visceral adipose tissue versus placebo in HIV lipodystrophy patients. MedlinePlus (a National Institutes of Health consumer resource) confirms Egrifta's approved indication and administration details as of its current listing.
What to know
Compounded medications are not FDA-approved, regardless of how similar the active ingredient is to an approved drug. Outside its one approved use, tesamorelin is not an established treatment.
The Halftime POV
We believe readers deserve a clear line between an approved drug and a compounded one. That means naming Egrifta's approval status clearly, and being equally clear when a compounded product isn't the same thing.
Related reading:
- Tesamorelin: who asks
- Tesamorelin: from HIV lipodystrophy to visceral fat research
- Category framework: who's affected
- FDA 503A bulks list explained
FAQ
Is tesamorelin FDA approved for visceral fat? Yes, for one use. Tesamorelin is FDA-approved as the brand Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy, a condition where the body redistributes fat abnormally. It is not FDA-approved for general fat loss in people without this diagnosis, and other uses are not established.
What is the regulatory status of compounded tesamorelin? Compounded tesamorelin is not approved as its own drug product. That means it has not gone through FDA review for safety, effectiveness, and manufacturing consistency the way Egrifta has.
Is compounded tesamorelin the same as Egrifta? No. Egrifta is an FDA-approved, agency-inspected product. Compounded tesamorelin is a different, pharmacy-prepared product, and FDA has not approved it. Sourcing, purity testing, and oversight can differ between the two.
Why does the approval-vs-compounding distinction matter? It affects what has actually been verified. An approved drug has documented trial data behind its specific use and FDA review of how it is made; a compounded version has not had that review.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved.
Sources
- Falutz, J. et al. "Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients." New England Journal of Medicine, 2007.
- MedlinePlus, National Institutes of Health. "Tesamorelin Injection." medlineplus.gov, accessed 2026.
- U.S. Food and Drug Administration. "Compounding and FDA: Questions and Answers." fda.gov.
- U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A." fda.gov.
Frequently asked questions
Is tesamorelin FDA approved for visceral fat?
Yes, for one use. Tesamorelin is FDA-approved as the brand Egrifta to reduce excess abdominal fat in adults with HIV and lipodystrophy, a condition where the body redistributes fat abnormally. It is not FDA-approved for general fat loss in people without this diagnosis, and other uses are not established.
What is the regulatory status of compounded tesamorelin?
Compounded tesamorelin is not approved as its own drug product. That means it has not gone through FDA review for safety, effectiveness, and manufacturing consistency the way Egrifta has.
Is compounded tesamorelin the same as Egrifta?
No. Egrifta is an FDA-approved, agency-inspected product. Compounded tesamorelin is a different, pharmacy-prepared product, and FDA has not approved it. Sourcing, purity testing, and oversight can differ between the two.
Why does the approval-vs-compounding distinction matter?
It affects what has actually been verified. An approved drug has documented trial data behind its specific use and FDA review of how it is made; a compounded version has not had that review.
